Brief: Mustang Bio - Holders Of Majority Of Voting Power Of Capital Stock Of Co Executed Written Consent Approving Grant Of Discretionary Authority To Board
Brief: Mustang Bio Provides Car T Cell Therapy Portfolio Updates
Brief: Mustang Bio Says On Nov 22, Notified By Nasdaq That Nasdaq Had Granted Co's Request To Transfer Listing Of Co's Common Stock To Nasdaq Capital Market Tier
U.S. RESEARCH ROUNDUP-Caterpillar, Endava, Harpoon Therapeutics
Mustang Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Mustang Bio Reports Third Quarter 2022 Financial Results
Mustang Bio Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Mustang Bio Announces Phase 1/2 Clinical Trial Data Of MB-106
Mustang Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Mustang Bio Reports Second Quarter 2022 Financial Results And Recent Corporate Highlights
Brief: Mustang Bio Announces First Patient Successfully Treated By Ex Vivo Lentiviral Gene Therapy To Treat Rag1 Severe Combined Immunodeficiency
Mustang Bio soars on orphan drug tag for blood cancer therapy
Brief: Mustang Bio Inc Says U.S. FDA Has Granted Orphan Drug Designation To MB-106
Brief: Mustang Bio Announces Updated Interim Results From Follicular Lymphoma Cohort Of Ongoing Phase 1/2 Clinical Trial Of MB-106, CD20-Targeted CAR T Therapy
Brief: Mustang Bio-On May 24, Received Letter From Staff Of Nasdaq, Co Not In Compliance With Minimum Bid Price Requirement Of Nasdaq Listing Rule
Brief: Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
Mustang Bio Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Mustang Bio Says Data On Treatment With Lentiviral Viral Vector Gene Therapy Selected For Oral Presentation
Brief: Mustang Bio Reports Updated Interim Data From Ongoing Clinical Trial Of MB-106